Why Standard Anticoagulation May Fail

Bruce M Rothschild, MD
Physician
IU Health

The surprisingly frequent failure of “potent” anticoagulation to prevent venous thromboembolism was the subject of this intriguing article. A possible explanation may be the presence of antibodies that modulate platelet function, which are referred to as antiphospholipid antibodies (1). This is especially pertinent to surgical prophylaxis, as the presence of antiphospholipid antibodies requires modification of standard intervention (2). Support for this hypothesis is predicated on aspirin’s effectiveness in this study, contrasted with the relatively poor performance of standard warfarin and low-molecular-weight heparin prophylaxis.

Standard warfarin dosing to achieve 2.0-3.0 INR is ineffective in preventing thromboembolic events in the presence of antiphospholipid antibodies (3). INRs of 3.0 to 3.5 are required. Fractionated heparins also are not effective in preventing thrombotic events in individuals with antiphospholipid syndrome (3,4). Thus, preventive measures for individuals with antiphospholipid antibodies are limited to three options:

1. Aspirin, with assessment of platelet function to assure platelet inhibition is successful.
2. Unfractionated heparin at standard doses.
3. Warfarin at sufficient doses to maintain INR between 3.0 and 3.5.

What assays are required to identify the presence of antiphospholipid antibodies? Antibodies to anticardiolipin (IgG, IgM, and IgA classes), to beta-2-glycoprotein I (IgG, IgM, and IgA classes) and to anti-phosphatidylserine/prothrombin (5). Such workup seems appropriate, at least among individuals who have a history of thromboembolic events.

References


Conflict of Interest: None Declared